<?xml version="1.0" encoding="UTF-8"?>
<ref id="bb0270">
 <label>53</label>
 <element-citation publication-type="journal" id="rf0260">
  <person-group person-group-type="author">
   <name>
    <surname>Griffin</surname>
    <given-names>M.P.</given-names>
   </name>
   <name>
    <surname>Khan</surname>
    <given-names>A.A.</given-names>
   </name>
   <name>
    <surname>Esser</surname>
    <given-names>M.T.</given-names>
   </name>
   <name>
    <surname>Jensen</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Takas</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Kankam</surname>
    <given-names>M.K.</given-names>
   </name>
  </person-group>
  <article-title>Safety, tolerability, and pharmacokinetics of MEDI8897, the respiratory syncytial virus prefusion F-targeting monoclonal antibody with an extended half-life, in healthy adults</article-title>
  <source>Antimicrob Agents Chemother</source>
  <volume>61</volume>
  <issue>3</issue>
  <year>2017</year>
  <ext-link ext-link-type="uri" xlink:href="pmid:27956428" id="ir0345" xmlns:xlink="http://www.w3.org/1999/xlink">27956428</ext-link>
  <comment>PMCPMC5328523</comment>
 </element-citation>
</ref>
